8-K: Insperity Reports Q4/FY25 Losses, Announces 4% Workforce Cut

Insperity, Inc. reported a net loss for both the fourth quarter and full year 2025, alongside an internal reorganization eliminating approximately 4% of non-sales positions.

Summary

• For Q4 2025, Insperity reported a net loss of $33 million, diluted EPS of $(0.88), adjusted EBITDA of $(13) million, and adjusted EPS of $(0.60).
• For the full year 2025, the company reported a net loss of $7 million, diluted EPS of $(0.19), adjusted EBITDA of $131 million, and adjusted EPS of $1.03.
• Revenues increased 3% in Q4 2025 to $1.7 billion and 4% for the full year 2025 to $6.8 billion.
• The average number of worksite employees (WSEEs) paid per month increased 1% in Q4 2025 to 312,377 and 1% for the full year 2025 to 310,089.
• Gross profit decreased 21% in Q4 2025 to $172 million and 14% for the full year 2025 to $900 million, primarily due to elevated benefits costs.
• Operating expenses decreased 6% in Q4 2025 to $218 million and 3% for the full year 2025 to $910 million.
• An internal reorganization was announced, expected to eliminate approximately 4% of non-sales positions and incur estimated one-time charges of $9 million, primarily for severance payments.
• The company returned $109 million to shareholders during 2025 through the repurchase of 232,000 shares at a cost of $19 million and $90 million in cash dividends.
• 2026 guidance includes Q1 Adjusted EPS of $1.03-$1.50 and Full Year Adjusted EPS of $1.69-$2.72, along with Q1 Adjusted EBITDA of $81-$111 million and Full Year Adjusted EBITDA of $170-$230 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging report, marked by significant net losses and declining profitability metrics, despite revenue growth. The internal reorganization and associated costs, coupled with a negative Q4 adjusted EBITDA, indicate operational difficulties, though management expresses optimism for 2026 recovery.

Positives

• Revenues increased 3% in Q4 2025 to $1.7 billion and 4% for the full year 2025 to $6.8 billion.
• Average paid WSEEs increased 1% in Q4 2025 to 312,377 and 1% for the full year 2025 to 310,089.
• Operating expenses decreased 6% in Q4 2025 to $218 million and 3% for the full year 2025 to $910 million.
• The company returned $109 million to shareholders in 2025 through share repurchases ($19 million) and cash dividends ($90 million).
• Management believes the year-end transition with a step up in gross profit margin positions the company for a significant recovery in profitability in 2026.
• New contract and plan design changes with UnitedHealthcare are expected to contribute to margin recovery.
• Disciplined hiring in sales and other key positions is expected to continue.

Negatives

• Reported a net loss of $33 million in Q4 2025 and $7 million for the full year 2025.
• Diluted EPS was $(0.88) in Q4 2025 and $(0.19) for the full year 2025.
• Adjusted EBITDA was $(13) million in Q4 2025.
• Gross profit decreased 21% in Q4 2025 to $172 million and 14% for the full year 2025 to $900 million, primarily due to continued elevated benefits costs driven by inpatient, outpatient, pharmacy trends, and large claim activity.
• An internal reorganization will eliminate approximately 4% of non-sales positions, incurring an estimated $9 million in one-time charges.
• Q1 2026 Adjusted EPS guidance shows a year-over-year decrease of 34% at the midpoint.
• Q1 2026 Adjusted EBITDA guidance shows a year-over-year decrease of 21% at the midpoint.
• Adjusted cash at December 31, 2025, totaled $57 million, a decrease from $134 million at December 31, 2024.
• Outstanding borrowings of $370 million remain under the $750 million credit facility.

Risks

• Adverse economic conditions.
• Disallowance of employee retention tax credits under certain COVID-19 relief programs.
• Bank failures or other events affecting financial institutions.
• Labor shortages, increasing competition for highly skilled workers, and evolving employee expectations regarding the workplace.
• Impact of inflation and changes in U.S. trade policy.
• Vulnerability to regional economic factors because of geographic market concentration.
• Failure to comply with covenants under the credit facility.
• Impact of a future outbreak of highly infectious or contagious disease.
• Liability for WSEE payroll, payroll taxes and benefits costs, or other liabilities associated with actions of client companies or WSEEs, including if clients fail to pay.
• Increases in health insurance costs and workers' compensation rates and underlying claims trends.
• Financial solvency of workers' compensation carriers, other insurers or financial institutions.
• The ability to adjust service fees for increases in state and local taxes, including state unemployment tax rates.
• An adverse determination regarding status as the employer of WSEEs for tax and benefit purposes and an inability to offer alternative benefit plans following such a determination.
• Cancellation of client contracts on short notice, or the inability to renew client contracts or attract new clients.
• Disruption from healthcare reform or the inability to secure competitive replacement contracts for health insurance and workers' compensation insurance at expiration of current contracts.
• Regulatory and tax developments and possible adverse application of various federal, state and local regulations.
• Failure to manage growth of operations and the effectiveness of sales and marketing efforts.
• The impact of the competitive environment and other developments in the human resources services industry, including the professional employer organization (PEO) industry, on growth and/or profitability.
• An adverse final judgment or settlement of claims against Insperity.
• Disruptions of information technology systems or failure to enhance service and technology offerings to address new regulations or client expectations.
• Liability or damage to reputation relating to disclosure of sensitive or private information as a result of data theft, cyberattacks or security vulnerabilities.
• Failure of third-party providers, such as financial institutions, data centers or cloud service providers.
• The ability to fully realize the anticipated benefits of the strategic partnership and joint solution with Workday, Inc.
• The ability to integrate or realize expected returns on future product offerings, including through acquisitions, strategic partnerships, and investments.

Future Outlook

The company expects a significant recovery in profitability in 2026, driven by emphasizing margin and profit recovery, regaining growth momentum through HR360 sales and retention initiatives, and the roll-out of HRScale. Management anticipates margin recovery through pricing, client selection, new contract and plan design changes with UnitedHealthcare, and operating expense efficiencies. The internal reorganization is expected to be substantially complete before the end of the first quarter of 2026.

Management Comments

• "We accomplished the key objective of our year-end transition with a step up in gross profit margin, which we believe positions the company for a significant recovery in profitability this year." Paul J. Sarvadi, Insperity Chairman and Chief Executive Officer.
• "As we enter 2026, we plan to continue emphasizing margin and profit recovery while regaining our growth momentum, which we expect will be achieved through HR360 sales and retention initiatives and the roll out of HRScale." Paul J. Sarvadi, Insperity Chairman and Chief Executive Officer.
• "We confronted the profitability challenges in 2025 and have taken significant steps designed to produce margin recovery through pricing and client selection, our new contract and plan design changes with UnitedHealthcare, and operating expense efficiencies." James D. Allison, Executive Vice President of Finance, Chief Financial Officer and Treasurer.
• "We plan to continue executing our strategy throughout 2026, furthering our efforts to drive a meaningful increase in adjusted EBITDA." James D. Allison, Executive Vice President of Finance, Chief Financial Officer and Treasurer.

Industry Context

StockSavvy.ai notes that the PEO industry, in which Insperity operates, is sensitive to macroeconomic conditions, employment trends, and healthcare costs. The reported elevated benefits costs and the workforce realignment reflect broader challenges in managing operational expenses and maintaining profitability in a competitive HR services market. The strategic partnership with Workday indicates a move towards integrating advanced technology solutions, a common trend in the HR tech space to enhance efficiency and service offerings.

Comparison to Industry Standards

• The reported net losses and significant decline in gross profit due to elevated benefits costs suggest Insperity is facing specific challenges that may diverge from more stable industry peers.
• The 1% WSEE growth is modest compared to some high-growth tech-enabled HR platforms, but within the range for established PEOs in a mature market.
• The internal reorganization to improve efficiency and align the workforce is a common strategy for companies looking to optimize operations, similar to actions taken by other large service providers facing margin pressures.
• The strategic partnership with Workday positions Insperity to leverage enterprise-grade HR technology, a move seen across the industry to enhance service delivery and client value, comparable to how other PEOs might integrate with platforms like ADP, Paychex, or proprietary systems.

Stakeholder Impact

• Shareholders are impacted by net losses, declining EPS, and the use of capital for share repurchases and dividends amidst profitability challenges, with potential for future recovery if 2026 guidance is met.
• Approximately 4% of non-sales employees will be impacted by job eliminations due to the internal reorganization.
• Client companies may benefit from improved efficiency and new offerings like HRScale, but could be affected by pricing adjustments and client selection strategies.
• Suppliers, such as UnitedHealthcare and Workday, continue their partnerships, with new contract terms for UnitedHealthcare.

Next Steps

• Continue emphasizing margin and profit recovery in 2026.
• Regain growth momentum through HR360 sales and retention initiatives.
• Roll out HRScale.
• Continue executing strategy throughout 2026 to drive a meaningful increase in adjusted EBITDA.
• Substantially complete the Realignment Plan before the end of the first quarter of 2026.
• Host a conference call on February 10, 2026, at 5:00 p.m. ET to discuss results and 2026 outlook.

Key Dates

Recommendation

While the company reported significant losses and a workforce reduction, management has outlined clear steps for margin recovery and expects a return to profitability in 2026, supported by new contracts and strategic initiatives. The 2026 guidance, particularly for full-year adjusted EBITDA, suggests a potential turnaround. An investor would likely hold to see if these strategic actions translate into the anticipated recovery, rather than selling on past losses or buying on future promises.

Keywords

Human Resources, PEO, Workforce Solutions, HR Services, Business Performance, Financial Results, Earnings, Reorganization, Layoffs, Benefits Costs, Worksite Employees, Adjusted EBITDA, EPS, Insperity